Clinical trial
A Study to Evaluate ALN-6222 in Participants With Obesity
Recruiting now · Phase 1 · 1 countries · Registry ID NCT07624071
Recruiting nowPhase 1Interventional
What this study is about
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 65 Years
SexAll
Healthy volunteersNot accepted
ConditionObesity
Full registry criteria
Inclusion Criteria - * Is an adult patient with a body mass index ≥30 kg/m\^2 to \<40 kg/m\^2 * Has a hemoglobin A1c \<6.5% Exclusion Criteria - * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5 times the upper limit of normal (ULN) * Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection * Has an estimated glomerular filtration (eGFR) of \<60 mL/min/1.73m\^2 at screening Note: other protocol defined inclusion / exclusion criteria apply
Treatments and study arms
ALN-6222
Drug
ALN-6222 will be administered subcutaneously (SC).
Placebo
Drug
Placebo will be administered SC.
Primary outcomes
Frequency of Adverse EventsUp to 12 months
Study locations
1 locations were listed when this page was built. The first 40 are shown.
Clinical Trial Site🇨🇦 Mount Royal, Canada